肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染*

doi:10.3969/j.issn.1672-5069.2019.05.003

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (5): 617-619.doi: 10.3969/j.issn.1672-5069.2019.05.003

肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*

廖桂婵, 彭颉, 张小勇

510515广州市南方医科大学南方医院感染内科肝病中心

收稿日期:2019-07-02 出版日期:2019-09-10 发布日期:2019-09-16
通讯作者: 张小勇,E-mail：xiaoyzhang@smu.edu.cn
作者简介:廖桂婵,女,27岁,硕士研究生。E-mail：guichan-liao@qq.com
基金资助:
国家自然科学基金资助项目（编号：81871664）

Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection

Liao Guichan, Peng Jie, Zhang Xiaoyong

Hepatology Unit,Nanfang Hospital,Southern Medical University,Guangzhou 510515,Guangdong Province,China

Received:2019-07-02 Online:2019-09-10 Published:2019-09-16

摘要/Abstract

关键词: 乙型肝炎, 肝细胞, Toll样受体, 天然免疫

Key words: Hepatitis B, Hepatocytes, Toll like receptor, Innate immunity

廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.

Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection[J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.

[1] Wieland SF,Chisari FV.Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol,2005,79:9369-9380.
[2] Cooper A,Tal G,Lider O,et al.Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol,2005,175:3165-3176.
[3] Lu HL,Liao F.Melanoma differentiation-associated gene 5 senses hepatitis B virus and activates innate immune signaling to suppress virus replication. J Imunol,2013,191:3264-3276.
[4] Sato S,Li K,Kameyama T,et al.The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity,2015,42:123-132.
[5] Hosel M,Quasdorff M,Wiegmann K,et al.Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology,2009,50:1773-1782.
[6] Williams JB,Huppner A,Mulrooney-Cousins PM,et al.Differential expression of Woodchuck Toll-like receptors 1-10 in distinct forms of infection and stages of hepatitis in experimental hepatitis B virus infection. Front Microbiol,2018,9:3007.
[7] Karimi-Googheri M, Arababadi MK.TLR3 plays significant roles against hepatitis B virus. Mol Biol Rep,2014,41:3279-3286.
[8] Chen Z,Cheng Y,Xu Y,et al.Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol,2008,128:400-408.
[9] Shahrakyvahed A,Sanchooli J,Sanadgol N,et al.TLR9:an important molecule in the fight against hepatitis B virus. Postgraduate Med J,2014,90:396-401.
[10] Tomasello E,Naciri K,Chelbi R,et al.Molecular dissection of plasmacytoid dendritic cell activation in vivo during a viral infection. EMBO Jl,2018,37:312-316.
[11] Visvanathan K,Skinner NA,Thompson AJ,et al.Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology,2007,45:102-110.
[12] Sitia G,Iannacone M,Aiolfi R,et al.Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog,2011,7:e1002061.
[13] Yao N,Wang X.In vitro immunomodulatory activity of oxymatrine on Toll-like receptor 9 signal pathway in chronic hepatitis B. Am J Chin Med,2014,42:1399-1410.
[14] Wu J,Lu M,Meng Z,et al.Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology,2007,46:1769-1778.
[15] Ting JP,Lovering RC,Alnemri ES,et al.The NLR gene family: a standard nomenclature. Immunity,2008,28 :285-287.
[16] Nosratabadi R,Alavian SM,Zare-Bidaki M,et al.Innate immunity related pathogen recognition receptors and chronic hepatitis B infection. Mol Immunol,2017,90:64-73.
[17] Zhao Q,Peng L,Huang W,et al.Rare inborn errors associated with chronic hepatitis B virus infection. Hepatology,2012,56:1661-1670.
[18] Askari A,Nosratabadi R,Khaleghinia M,et al.Evaluation of NLRC4,NLRP1,and NLRP3,as components of inflammasomes,in chronic hepatitis B virus-infected patients. Viral Immunol,2016,29:496-501.
[19] Yoshino H,Saitoh T,Kozakai M,et al.Effects of ionizing radiation on retinoic acid-inducible gene-I-like receptors. Biomed Rep,2015,3:59-62.
[20] Han Q,Hou Z,Yin C,et al.5'-triphosphate siRNA targeting HBx elicits a potent anti-HBV immune response in pAAV-HBV transfected mice. Antiviral Res,2019,161:36-45.
[21] Chen X,Qian Y,Yan F,et al.5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells. Eur J Pharmacol,2013,721:86-95.
[22] Isogawa M,Robek MD,Furuichi Y,et al.Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol,2005,79:7269-7272.
[23] Zhang B,Liu Y,Wang X,et al.TLR3 activation of hepatic stellate cell line suppresses HBV replication in HepG2 cells. Front Immunol,2018 9:2921.
[24] Lanford RE,Guerra B,Chavez D,et al.GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology,2013,144:1508-1517.

肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*

Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[7]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[8]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[9]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[10]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[11]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[12]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[13]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[14]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[15]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.